08/09/2025
Russia is reportedly preparing to begin human clinical trials for a personalized mRNA cancer vaccine, with initial reports suggesting an estimated production cost of approximately 300,000 rubles per dose, or about 252,000 Indian rupees. The vaccine, developed by the Gamaleya National Research Center, is designed to teach the immune system to target cancer cells, and early trials are set to focus on colorectal cancer. While preclinical trials showed promising results, the vaccine awaits final approval from Russia's Ministry of Health.